Research
Hormonal
SGLT2 inhibitors improve cardiovascular outcomes in heart failure patients, including those with preserved and reduced ejection fraction, independent of diabetes status.
If you have heart failure, ask your doctor about SGLT2 inhibitors. They are now recommended for heart failure patients regardless of whether they have diabetes, as they significantly improve outcomes.
StrongSupportsVERY_HIGH confidence
Sodium-glucose cotransporter 2 inhibitors in heart failure with reduced ejection fraction... heart failure with preserved ejection fraction and heart failure with mildly reduced ejection fraction... in acute heart failure.
Why this rating
Based on major clinical trials referenced in the review.
Source
Modern antidiabetic therapy by sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide 1 receptor agonists, and dipeptidyl peptidase 4 inhibitors against cardiovascular diseases
Sebastian Steven et al. · Pharmacological Reviews · 2025
DOI 10.1016/j.pharmr.2025.100082
narrative_reviewCited 12×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- SGLT2 inhibitors, GLP-1 receptor agonists, and DPP-4 inhibitors provide cardiovascular organ protection in type 2 diabetes through direct antioxidant and anti-inflammatory mechanisms, independent of glucose lowering.Good
- GLP-1 receptor agonists reduce platelet aggregation and thrombus formation, thereby mitigating the risk of thrombotic cardiovascular events in diabetic patients.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →